ntra-Cellular Therapies Announces Progression to Higher Dose Cohort in ITI-214 Study
Intra-Cellular Therapies announced the successful completion of the second dose cohort (single dose of 30 mg administered orally) in Study ITI-214-104 (Study ‘104) ...
September 27, 2019
by americanpharmaceuticalreview
Dapagliflozin Lowers Risk for Worsening Heart Failure
For patients with heart failure and reduced ejection fraction, dapagliflozin is associated with a lower risk for worsening heart failure or death from cardiovascular causes, regardless of the presence of type 2 diabetes ...
September 24, 2019
by drugs
SGLT2 Inhibitors Linked to Lower Risk for Heart Failure
Use of sodium glucose cotransporter 2 (SGLT2) inhibitors for type 2 diabetes is associated with a reduced risk for heart failure ...
September 23, 2019
by drugs
FDA grants Fast Track designation for Farxiga in heart failure
AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to reduce the risk of cardiovascular (CV) death...
September 18, 2019
by worldpharmanews
Fast Track designation given to heart failure treatment
Farxiga (dapagliflozin) has been given Fast Track designation by the FDA to reduce the risk of cardiovascular death.
September 18, 2019
by europeanpharmaceuticalreview
Novartis’s heart failure drug Entresto presents mixed trial results
Novartis has announced that its heart failure with reduced ejection fraction (HFrEF) drug Entresto (sacubitril/valsartan) has shown further efficacy in two Phase IV trials, PROVE-HF and EVALUATE-HF.
September 4, 2019
by pharmaceutical-technology
Poor HIV Control Ups Risk for Sudden Cardiac Death in Heart Failure
Persons living with HIV (PHIV) who are hospitalized with heart failure are at an increased risk for subsequent sudden cardiac death (SCD)...
August 26, 2019
by drugs
Asian Study Finds Diabetes, Heart Failure a Dangerous Duo
Asian heart failure patients who also have type 2 diabetes can develop changes in the structure of their heart and are at increased risk for hospitalizations and premature death, a new study finds.
August 22, 2019
by drugs
Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure
AstraZeneca announced positive results from the landmark Phase III DAPA-HF trial which showed that Farxiga (dapagliflozin) met the primary composite endpoint with a statistically-significant and ...
August 21, 2019
by worldpharmanews
Excess Risk for Diabetes-Linked Heart Failure Greater in Women
The excess risk for heart failure associated with diabetes is significantly greater in women than men, according to a meta-analysis published online in Diabetologia.
July 22, 2019
by drugs
Image-Based Model Predicts Radiation Tx Failure in Lung Cancer
Image-Based Model Predicts Radiation Tx Failure in Lung Cancer.
July 4, 2019
by drugs
Microbes Tied to Pedicle Screw Loosening, Spinal Implant Failure
Microbes Tied to Pedicle Screw Loosening, Spinal Implant Failure.
June 13, 2019
by drugs